Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-04-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2022年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2022 年第一季度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2022 First Quarter Report Full Text." It contains detailed financial data including balance sheets, profit and loss statements, cash flow information, shareholder information, and notes on financial performance for the first quarter of 2022. The document is approximately 15,000 characters long, indicating a comprehensive report rather than a brief announcement. The presence of quarterly financial statements and detailed financial metrics confirms this is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-18 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the reasons for the change, the new accounting standards adopted, the decision-making process by the board and supervisory committee, and includes independent opinions from directors and supervisors. The document does not contain financial statements or detailed financial data but serves as a formal disclosure of the accounting policy change. It is not a full annual or interim report, audit report, or earnings release. Given its nature as a formal announcement about accounting policy changes, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2022-04-18 Chinese
第五届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's board of directors meeting (第五届董事会第二十七次会议决议公告). It includes details about the meeting date, attendance, and resolutions passed, such as approval of the 2022 Q1 report, application for industrial property adjustment, and accounting policy changes. It does not contain the full quarterly report or detailed financial statements but references where the report can be found. This is a typical format for a Board/Management Information announcement regarding board meeting decisions and approvals. Therefore, the document fits best under Board/Management Information (MANG). The document length is short (1478 characters), consistent with an announcement rather than a full report.
2022-04-18 Chinese
关于深圳信立泰药业股份有限公司2021年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by Guangdong Huashang Law Firm regarding the 2021 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the legality of the AGM's convening, attendance, voting procedures, and results. The document does not contain financial statements or detailed financial performance data but focuses on the procedural and legal aspects of the AGM. The document length is 6118 characters, which is sufficient to be a substantive legal opinion rather than a brief announcement. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the AGM.
2022-04-18 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the 2021 Annual General Meeting (AGM) resolutions of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the meeting date, attendance, voting results on various proposals including the 2021 annual report, profit distribution plan, and other corporate governance matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or detailed financial statements. The length is 4342 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on the meeting proceedings and voting outcomes, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-04-18 Chinese
关于变更公司注册资本、修改公司章程的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of changes to the company's registered capital and amendments to the company articles of association. It details the increase in registered capital following a non-public stock issuance and the completion of related industrial and commercial registration changes. The document does not contain financial statements or detailed financial performance data but rather informs about capital structure changes and corporate governance document amendments. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is short and focused on capital changes, not a full report or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2022-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.